Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, ...

"The absence of a statistically significant benefit of adjuvant chemotherapy in the ASTER 70s trial underlines the persistent ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

Q2 2025 Earnings Call Transcript July 29, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.04, expectations were $1.39. Operator: Greetings, and welcome to the Incyte Second ...

Contract dispute settlement In May 2025, Incyte and Novartis entered into a settlement agreement with respect to litigation relating to the duration of royalty payments owed under the Collaboration ...

Incyte swung to a second-quarter profit on a sharp increase in revenue, and the company boosted 2025 sales projections for its cancer drugs. The maker of cancer drugs and other pharmaceuticals ...

Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company’s clinical development portfolio. "As I begin my tenure as ...

WILMINGTON, Del. (AP) — WILMINGTON, Del. (AP) — Incyte Corp. (INCY) on Tuesday reported second-quarter net income of $405 million. The Wilmington, Delaware-based company said it had profit of ...

WILMINGTON, Del. (AP) — WILMINGTON, Del. (AP) — Incyte Corp. (INCY) on Tuesday reported second-quarter net income of $405 million. The Wilmington, Delaware-based company said it had profit of ...